[ad_1]
Vaccination studies against Covid-19 continue by the ERÜ Vaccine Research and Development Center (ERAGEM) and the Center for Research and Good Clinical Practices. The first dose of the vaccine, which is the closest to widespread application among national vaccine candidates and in human trials, was administered to 44 volunteers in early November. After the administration of the first dose, which had no significant side effects, the administration of the second dose was started on November 26. The second dose of Phase 1 was administered to 44 volunteers. Phase 1 studies have been completed as of today, with the administration of the second dose to 44 volunteers.
ERÜ Rector Mustafa Çalış said: “The second phase 1 dosage of our local vaccine, which was developed by our university against Covid-19 and with the support of the Ministry of Health, was completed today and no effects were observed. serious secondary “. We are planning to pass, “he said.
On the other hand, it was reported that 200 volunteers were planned to be vaccinated within the scope of Phase-2.
THIS VIDEO MAY HAVE YOUR INTEREST
